惡性腫瘤又稱作癌症，在近年來成為伴生動物的主要死亡原因之一，且國人罹患癌症導致死亡的比例也是居高不下；癌症是細胞的不正常增生，這些增生會藉由體內的循環系統與淋巴系統，進而轉移到身體其他部分，令患者異常出血與慢性咳嗽，嚴重可能導致死亡，而治療方法主要以手術治療、放射線治療、化學治療等，但產生的副作用較多，這些副作用甚至會加深患者的疾病。
近年來學者們致力研究熱消融之技術，為了改善侵入與非侵入性手術所帶來的副作用與危險性，但目前熱銷融技術須克服因組織吸收而限制加熱的深度，以及高強度聚焦超聲雖然深度足夠，但會引起皮膚灼燒的副作用。
本研究藉由液態鎵與氧化鐵(Fe3O4)結合成新型態的複合粒子，用交變磁場感應加熱的方式來使鎵基磁粒子升溫，以熱燒灼的方法達到治療癌細胞腫瘤的目的，而氧化鐵(Fe3O4)則讓鎵基磁粒子帶來良好的磁控性，讓治療上有局部治療與指引的功能性。鎵基磁粒子的配置上是由多顆氧化鐵(Fe3O4)聚集，並藉由液態鎵作為其黏合劑沾黏在多顆氧化鐵中，合成後與液態鎵、氧化鐵(Fe3O4)進行感應加熱實驗，比較本研究對於鎵基磁粒子的升溫趨勢與產熱效果，並量測磁滯曲線來確認鎵基磁粒子的磁性。
量測結果顯示鎵基磁粒子在合成後其磁性降低，但仍可以藉由其磁性進行吸附與吸引，並藉由調整加熱時間與磁場就可以達到控制熱治療的範圍與效果。動物實驗的部分，將鎵基磁粒子注射至腫瘤內的產熱溫度雖無液態鎵高，但其熱銷融的穩定性及定位性遠勝於液態鎵。

Malignant tumors, also known as cancers, have become one of the leading causes of death in companion animals in recent years, and the proportion of deaths caused by cancer in people is also high. The cancer is abnormal cell proliferation. The circulatory and lymphatic systems expand the cancer cells in the body, then transferred to other parts of the body, causing abnormal bleeding and chronic coughing, finally leading to death. The treatment methods are mainly surgery, radiation therapy, chemotherapy, etc.; however, many side effects may even cause Deepen the patient's disease.
In recent years, scholars have devoted themselves to researching hot-melt technology to improve the side effects and risks caused by invasive and non-invasive surgery. However, current hot-melt technology must overcome the depth of heating due to tissue absorption and high-intensity focused ultrasound. Although the depth is enough, it will cause the side effects of skin burning.
In this research, liquid gallium and magnetic particles (Iron oxide, Fe3O4) are combined to form a new state of composite particles. The gallium-based magnetic particles are heated by alternating magnetic field induction heating to treat cancer cell tumors by thermal cauterization. Iron oxide (Fe3O4) allows gallium-based magnetic particles to bring reasonable magnetic control, allowing local treatment and guidance functions in treatment. The configuration of gallium-based magnetic particles is composed of multiple iron oxides (Fe3O4) aggregated, and liquid gallium is used as its binder to adhere to numerous iron oxides. After synthesis, they are heated by induction heating with liquid gallium and iron oxide (Fe3O4). Experiment, compare the heating trend and heat generation effect of this study on gallium-based magnetic particles and measure the hysteresis curve to confirm the magnetism of gallium-based magnetic particles.
The measurement results show that gallium-based magnetic particles have reduced magnetism after synthesis, but they can still be adsorbed and attracted by their magnetism. By adjusting the heating time and magnetic field, the range and effect of the thermal treatment of gallium-based magnetic particles could be controlled. In the part of animal experiments, gallium-based magnetic particles are injected into tumors. The thermal treatment effect of gallium-based magnetic particles is not better than liquid gallium, but its stability and positioning are far better than liquid gallium.

[1]. Lay, C. L. F. J. G. (2006). 環境污染與惡性腫瘤空間關係─ 以癌症地圖之肝癌及肺癌為例. Journal of Cartography, (16), 205-220.
[2]. 李欣慈, 趙詩瑾, 廖珍娟, & 周桂如. (2005). 腫瘤治療新趨勢: 標靶治療. 腫瘤護理雜誌, 5(2), 29-42.
[3]. Kim, E., Kim, J. Y., Smith, M. A., Haura, E. B., & Anderson, A. R. (2018). Cell signaling heterogeneity is modulated by both cell-intrinsic and-extrinsic mechanisms: An integrated approach to understanding targeted therapy. PLoS biology, 16(3), e2002930
[4]. Sukhoruchkin, S. I., & Soroko, Z. N. (2009). Graphs for 31-Ga (Gallium). Landolt Börnstein, 22, 8079.
[5]. Dickey, M. D., Chiechi, R. C., Larsen, R. J., Weiss, E. A., Weitz, D. A., & Whitesides, G. M. (2008). Eutectic gallium‐indium (EGaIn): a liquid metal alloy for the formation of stable structures in microchannels at room temperature. Advanced functional materials, 18(7), 1097-1104..
[6]. Goldberg, S. N., Gazelle, G. S., & Mueller, P. R. (2000). Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American journal of roentgenology, 174(2), 323-331..
[7]. HC, D., GE, M., & LA RUE, H. C. (1949). Studies of the metabolism of gallium. The Journal of pharmacology and experimental therapeutics, 96(2), 135-138.
[8]. Chitambar, C. R. (2010). Medical applications and toxicities of gallium compounds. International journal of environmental research and public health, 7(5), 2337-2361.
[9]. Wang, X., Guo, R., & Liu, J. (2019). Liquid metal based soft robotics: materials, designs, and applications. Advanced Materials Technologies, 4(2), 1800549.
[10]. Edwards, C.L.; Hayes, R.L. Tumor scanning with 67Ga citrate. J. Nucl. Med. 1969, 10, 103-105
[11]. Bayerl, T., Duhovic, M., Mitschang, P., & Bhattacharyya, D. (2014). The heating of polymer composites by electromagnetic induction–A review. Composites Part A: Applied Science and Manufacturing, 57, 27-40.
[12]. King, S.C.; Reiman, R.J.; Prosnitz, L.R. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J. Clin. Oncol. 1994, 12, 306-311.
[13]. van Amsterdam, J.A.; Kluin-Nelemans, J.C.; van Eck-Smit, B.L.; Pauwels, E.K. Role of 67Ga scintigraphy in localization of lymphoma. Ann. Hematol. 1996, 72, 202-207.
[14]. Hart, M.M.; Adamson, R.H. Antitumor activity and toxicity of salts of inorganic group IIIa metals: aluminum, gallium, indium and thallium. Proc. Natl. Acad. Sci. USA 1971, 68, 1623-1626.
[15]. Foster, B.J.; Clagett-Carr, K.; Hoth, D.; Leyland-Jones, B. Gallium nitrate: The second metal with clinical activity. Cancer Treat. Rep. 1988, 70, 1311-1319.
[16]. Whitacre, C.; Apseloff, G.; Cox, K.; Matkovic, V.; Jewell, S.; Gerber, N. Suppression of experimental autoimmune encephalomyelitis by gallium nitrate. J. Neuroimmunol. 1992, 39, 175-181.
[17]. Matkovic, V.; Balboa, A.; Clinchot, D.; Whitacre, C.; Zwilling, B.; Brown, D.; Weisbrode, S.E.; Apseloff, G.; Gerber, N. Gallium prevents adjuvant arthritis in rats and interferes with macrophage/T-cell function in the immune response. Curr. Ther. Res. 1991, 50, 255-267.
[18]. Orosz, C. G., Wakely, E., Bergese, S. D., VanBuskirk, A. M., Ferguson, R. M., Mullet, D., ... & Gerber, N. (1996). Prevention of murine cardiac allograft rejection with gallium nitrate: comparison with Anti-CD4 Monoclonal Antibody1. Transplantation, 61(5), 783-791.
[19]. Orosz, C.G.; Wakely, E.; Bergese, S.D.; Vanbuskirk, A.M.; Ferguson, R.M.; Mullet, D.; Apseloff, G.; Gerber, N. Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. Transplantation 1996, 61, 783-791.
[20]. Johnston, G. S. (1981). Clinical applications of gallium in oncology. International journal of nuclear medicine and biology, 8(4), 249-255.
[21]. Goldberg, S. N., Gazelle, G. S., & Mueller, P. R. (2000). Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American journal of roentgenology, 174(2), 323-331.